mucos
surfac
form
boundari
exterior
environ
function
main
gateway
pathogen
enter
host
via
respiratori
gastrointestin
andor
genit
tract
henc
properli
function
mucos
immun
import
protect
invad
pathogen
ideal
vaccin
infecti
pathogen
prime
host
induct
pathogenspecif
memori
immun
respons
appropri
mucos
compart
therebi
prevent
entri
andor
replic
invad
pathogen
site
infect
previou
studi
establish
mucos
vaccin
effici
stimul
local
mucos
immun
broadli
function
system
immun
suggest
mucos
vaccin
deliveri
may
profici
method
induc
pathogenspecif
secretori
antibodi
respons
well
cytotox
lymphocyt
ctl
respons
target
mucos
tissu
accordingli
studi
also
report
mucos
vaccin
highli
effect
confer
protect
variou
mucos
pathogen
nevertheless
vaccin
current
use
administ
via
parenter
rout
although
parenter
vaccin
effect
elicit
gener
system
immun
respons
ineffici
stimul
mucos
immun
exampl
deliv
influenza
vaccin
via
parenter
rout
reli
system
induct
igg
antibodi
protect
howev
studi
report
influenza
vaccin
efficaci
close
correl
immun
respons
induc
within
respiratori
mucosa
parenter
vaccin
use
present
shown
ineffici
stimul
immun
respons
respiratori
mucosa
recent
year
number
studi
explor
potenti
sublingu
immun
elicit
desir
immun
respons
variou
potenti
vaccin
compon
includ
solubl
protein
antigen
viruslik
particl
inactiv
liveattenu
virus
studi
success
demonstr
safeti
efficaci
sublingu
immun
induc
antigenspecif
system
mucos
immun
respons
protect
pathogen
challeng
review
provid
overview
previou
studi
describ
promis
prospect
sublingu
immun
vaccin
deliveri
current
sublingu
rout
wide
use
deliv
sublingu
immunotherapi
slit
treatment
type
allerg
hypersensit
repeat
sublingu
administr
allergen
shown
induc
allergenspecif
immun
respons
mediat
skew
allerg
respons
treg
induct
andor
activ
result
reduct
allerg
symptom
follow
subsequ
exposur
exampl
studi
conduct
kildsgaard
et
al
report
slit
treatment
allergen
sensit
mice
increas
cell
prolifer
well
level
allergenspecif
iga
bronchoalveolar
lavag
bal
nasal
lavag
nal
detect
allergenspecif
ige
anoth
studi
conduct
brimn
et
al
report
slit
treatment
allergensensit
mice
reduc
allerg
symptom
eosinophilia
allergenspecif
nal
serum
ige
level
upon
allergen
challeng
importantli
sublingu
antigen
administr
shown
safe
report
case
anaphylact
shock
clinic
studi
perform
children
although
mild
moder
local
advers
effect
observ
one
phase
studi
evalu
toxic
grass
pollen
tablet
base
observ
research
institut
evalu
use
sublingu
rout
vaccin
deliveri
first
studi
conduct
cuburu
et
al
group
mice
receiv
differ
concentr
ova
use
model
solubl
protein
antigen
togeth
cholera
toxin
ct
mucos
adjuv
follow
immun
ovaspecif
system
mucos
antibodi
level
well
cytokin
cytotox
lymphocyt
ctl
respons
examin
result
studi
show
sublingu
ovaimmun
induc
system
mucos
antibodi
respons
specif
administ
antigen
magnitud
antibodi
respons
gener
sublingu
immun
compar
observ
intranas
immun
significantli
greater
elicit
orogastr
immun
author
also
describ
sublingu
deliveri
ova
promot
prolifer
ovaspecif
cell
mix
cytokin
profil
signific
induct
ovaspecif
ctl
respons
local
system
manner
moreov
followup
studi
group
investig
efficaci
sublingu
administr
nonrepl
antigen
establish
antigenspecif
immun
genit
mucosa
confer
protect
human
papillomaviru
viru
hpv
studi
demonstr
sublingu
immun
mice
ova
ct
adjuv
induc
ovaspecif
iga
igg
sera
cervicovagin
secret
induct
ovaspecif
antibodi
cervicovagin
secret
associ
migrat
antibodi
secret
cell
asc
genit
mucosa
interestingli
sublingu
intranas
intravagin
immun
evok
compar
genit
asc
respons
intragastr
immun
fail
gener
signific
antibodi
respons
genit
mucosa
sublingu
immun
ova
induc
ovaspecif
ctl
genit
mucosa
although
induct
ctl
respons
requir
presenc
ct
adjuv
anoth
aspect
studi
determin
whether
deliveri
vaccin
antigen
via
sublingu
rout
could
actual
confer
protect
live
viru
challeng
accordingli
author
administ
sublingu
deliveri
human
papillomaviru
viruslik
particl
hpvlp
without
ct
adjuv
observ
hpvlpimmun
confer
protect
genit
challeng
human
papillomaviru
pseudovirion
similar
note
studi
conduct
hervouet
et
al
demonstr
sublingu
immun
mice
revers
transcriptas
polypeptid
use
cholera
toxin
b
subunit
ctb
adjuv
induc
iga
antibodi
asc
well
revers
transcriptasespecif
ctl
respons
genit
mucosa
mir
mucos
immun
respons
compar
immun
respons
gener
intranas
system
immun
nd
determin
protect
pseudoviru
challeng
taken
togeth
studi
recogn
sublingu
mucosa
potenti
rout
vaccin
deliveri
promot
induct
broadli
distribut
humor
cellmedi
immun
respons
system
lymphoid
tissu
well
variou
mucos
compart
offer
protect
pathogen
possess
tropism
mucos
epithelia
howev
result
recent
human
studi
investig
effect
sublingu
immun
licens
quadraval
human
papilloma
viru
hpv
vaccin
gardasil
sanofi
pasteur
contain
viruslik
particl
vlp
repres
four
hpv
type
less
encourag
studi
eighteen
healthi
adult
femal
volunt
immun
three
time
gardasil
week
via
either
sublingu
intramuscular
rout
result
demonstr
intramuscular
deliveri
elicit
hpvspecif
pseudovirusneutr
serum
cervicovagin
igg
prime
circul
ac
respons
howev
sublingu
deliveri
gener
lower
serum
lower
cervicovagin
igg
level
intramuscular
deliveri
induc
neutral
antibodi
respons
subject
moreov
neither
rout
substanti
increas
hpvspecif
mucos
iga
indic
challeng
lie
ahead
optim
immun
respons
follow
sublingu
immun
hpv
vaccin
human
adopt
sublingu
vaccin
deliveri
establish
protect
respiratori
pathogen
explor
sever
studi
tabl
studi
publish
song
et
al
mice
sublingu
immun
formalininactiv
live
influenza
viru
protect
lethal
influenza
viru
challeng
author
conclud
observ
protect
mediat
induct
influenza
virusspecif
igg
iga
serum
respiratori
mucosa
respect
limit
viru
entri
replic
respiratori
mucosa
addit
sublingu
deliveri
formalininactiv
viru
presenc
mucos
adjuv
ctaltb
induc
system
expans
cell
virusspecif
cytotox
lymphocyt
respons
although
author
expound
upon
mechan
virusspecif
ctl
respons
prime
follow
immun
nonrepl
inactiv
viru
particl
special
microenviron
within
proxim
drain
lymph
node
sublingu
mucosa
andor
crosspresent
vaccin
antigen
within
antigen
present
cell
apc
may
promot
induct
influenza
virusspecif
ctl
respons
observ
studi
moreov
studi
demonstr
singl
sublingu
administr
live
viru
caus
patholog
establish
broadrang
protect
influenza
viru
subtyp
without
risk
potenti
passag
vaccin
viru
olfactori
bulb
recent
studi
park
et
al
also
report
sublingu
administr
liveattenu
influenza
viru
lack
nonstructur
protein
safe
effect
induc
protect
homoand
heterosubtyp
influenza
viru
challeng
studi
mice
given
sublingu
administr
recombin
influenza
viru
design
respect
subsequ
develop
protect
immun
gener
sublingu
deliveri
liveattenu
influenza
viru
vaccin
evalu
result
promis
sublingu
administ
liveattenu
influenza
viru
vaccin
offer
crosssubtyp
protect
protect
efficaci
compar
induc
intranas
immun
vaccin
furthermor
studi
laboratori
also
evalu
protect
efficaci
gener
sublingu
deliveri
influenza
viru
subunit
vaccin
one
studi
recombin
influenza
viru
proteinbas
subunit
vaccin
contain
three
tandem
copi
express
escherichia
coli
protect
efficaci
parenter
sublingu
immun
compar
observ
parent
immun
induc
robust
antibodi
respons
serum
fail
provid
complet
protect
lethal
challeng
influenza
viru
meanwhil
sublingu
immun
result
signific
decreas
serum
antibodi
level
compar
parent
vaccin
howev
sublingu
immun
confer
superior
protect
influenza
viru
challeng
substanti
level
mucos
antibodi
detect
saliva
nasal
wash
bal
sublingu
immun
mice
studi
success
demonstr
sublingu
deliveri
improv
protect
efficaci
subunit
vaccin
compar
parenter
deliveri
improv
protect
efficaci
attribut
effect
induct
antigenspecif
antibodi
respons
airway
mucosa
anoth
studi
publish
laboratori
recombin
influenza
viru
hemagglutinin
protein
deriv
pandem
influenza
viru
express
e
coli
administ
mice
via
sublingu
rout
combin
ct
adjuv
sublingu
immun
induc
neutral
antibodi
respons
serum
respiratori
mucosa
provid
complet
protect
lethal
challeng
pandem
influenza
viru
furthermor
protect
efficaci
induc
sublingu
immun
compar
induc
parenter
immun
collect
grow
bodi
evid
suggest
sublingu
deliveri
inactiv
liveattenu
recombin
protein
influenza
viru
vaccin
safe
effect
confer
protect
influenza
viru
infect
offer
altern
strategi
parenter
vaccin
deliv
influenza
viru
vaccin
sublingu
mucosa
may
also
promis
vaccin
deliveri
rout
respiratori
pathogen
includ
respiratori
syncyti
viru
rsv
sever
acut
respiratori
syndrom
sar
viru
recent
studi
publish
kim
et
al
evalu
bacteriallyexpress
subunit
vaccin
design
gcf
encompass
central
conserv
region
within
rsv
g
glycoprotein
author
report
sublingu
immun
mice
gcf
elicit
strong
serum
igg
mucos
iga
respons
effect
reduc
lung
viru
titer
follow
rsv
challeng
absenc
cytokin
respons
pronounc
pulmonari
eosinophilia
studi
importantli
demonstr
sublingu
deliveri
rsv
gbase
subunit
vaccin
prevent
rsv
infect
without
prime
vaccineinduc
diseas
enhanc
affirm
sublingu
immun
viabl
deliveri
option
rsv
subunit
vaccin
furthermor
studi
conduct
laboratori
examin
sublingu
deliveri
recombin
adenoviru
vector
express
sar
spike
protein
radv
gener
sar
virusspecif
immun
respons
report
sublingu
administr
radv
mice
induc
sar
virusspecif
neutral
antibodi
respons
serum
secretori
iga
respons
respiratori
mucosa
observ
antibodi
respons
similar
magnitud
induc
follow
intranas
administr
radv
addit
sublingu
immun
significantli
increas
frequenc
sar
viru
proteinspecif
cell
lung
compar
intramuscular
immun
importantli
unlik
intranas
administr
sublingu
immun
radv
pose
minimum
risk
potenti
retrograd
passag
vaccin
compon
cn
shown
absenc
adenovir
dna
olfactori
bulb
overal
find
provid
evidenti
support
adopt
sublingu
vaccin
strategi
administr
vaccin
variou
respiratori
pathogen
mani
question
regard
sublingu
immun
still
remain
address
includ
use
proper
adjuv
optim
vaccin
formul
enhanc
vaccin
efficaci
howev
studi
describ
review
demonstr
promis
aspect
sublingu
immun
studi
sublingu
immun
shown
safe
highli
effect
gener
robust
immun
respons
administ
antigen
moreov
shown
confer
protect
immun
simultan
elicit
system
igg
mucos
iga
antibodi
well
ctl
respons
peripher
lymphoid
organ
mucos
tissu
studi
also
suggest
sublingu
immun
could
better
altern
tradit
parent
rout
vaccin
deliveri
genit
respiratori
pathogen
taken
togeth
find
describ
review
provid
foundat
evalu
novel
promis
rout
vaccin
deliveri
